Analyst Scoreboard: 9 Ratings For 10x Genomics
Portfolio Pulse from Benzinga Insights
In the past three months, 9 analysts have provided ratings for 10x Genomics (NASDAQ:TXG), showing a range of sentiments from bullish to bearish. The average 12-month price target has decreased by 26.94% to $39.0. Analysts have recently lowered their price targets, reflecting a negative shift in sentiment.
June 25, 2024 | 2:00 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Analysts have shown a negative shift in sentiment for 10x Genomics, lowering the average 12-month price target by 26.94% to $39.0. Recent ratings include downgrades and reduced price targets from several major firms.
The decrease in the average price target and the downgrades from major analyst firms indicate a negative outlook for 10x Genomics in the short term. This is likely to put downward pressure on the stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100